

Ref: MHL/Sec&Legal/2020-21/173

Date: February 10, 2021

To,
**Head, Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release as mentioned below:

'Metropolis Healthcare Limited records 23% growth in Revenue; EBITDA Margin expands by 430 bps YoY to 32.6%.'

You are requested to take the above information on record.

Thanking You,

Yours Faithfully

For **Metropolis Healthcare Limited**



Poonam Tanwani
Company Secretary & Compliance Officer
Membership No. A19182
Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Ltd records 23% growth in Revenue; EBITDA Margin expands by 430 bps YoY to 32.6%

Continued traction in Non-COVID testing, sustained cost optimization efforts has led to robust revenue & profitability in Q3FY21

- Conducted 5.1 Million Tests from 2.7 Million Patient Visits
- 23% YoY revenue growth, industry leading performance
- Share of B2C Business in Focus Cities at 61% in Q3FY21 (Non-COVID revenue), in-line with our plan to achieve 65% B2C contribution in focus cities in coming years.
- Metropolis' acquisition of Hitech diagnostics will strengthen its position as 2nd largest Diagnostics company in India and largest brand in South and West India
- The board of directors have declared an interim dividend of Rs. 8 per share

Mumbai, February 10, 2021: Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its audited consolidated financial results today for the third quarter (Q3FY21).

Financial Highlights

INR. 275 cr

+23%YoY

Revenue

61%

+700 bps YoY

**Revenue Share of B2C in Focus
Cities (Non-Covid)**

2.7 Mn

No. of Patients

We are pleased to post yet another strong performance with revenues growing 23% on a YoY basis. With our track record of successful acquisitions and integrations, we expect a smooth full integration of Hitech diagnostics as well as enhanced profitability through revenue and cost synergies. Our strategy to increase B2C contribution in focus cities for both COVID and Non COVID revenues is on track and will be aided by strategic network expansion, integrated brand building campaigns and providing a superior consumer experience. We expect Non COVID revenues to continue its growth trajectory as elective surgeries and outpatient visits are seeing a gradual up-tick. We will continue our focus on expanding our test menu, ramping up our home services and delivering a more digital and seamless experience to patients.

Ameera Shah, Promoter & Managing Director, Metropolis Healthcare Ltd

MEDIA RELEASE

GLOBAL ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah won the Leader of the Year Award by CNBC-AWAAZ CEO Award

Metropolis won the Most Admired Healthcare Company of the Year and our CEO, Mr. Vijender Singh won the "Best Business Leader of the Year" award at Business Leader of the Year Awards, 2020

Metropolis won the award for Best IT Practices at the Data Center Summit, 2019

Metropolis won the 'Best Logistics Network Optimization' & 'Best use of Technology in Logistics' awards announced at the 5th Asian Supply Chain Thought Leadership Summit & Awards in Mumbai.

Our Chairman, Dr. Sushil Shah, won the 'Lifetime Achievement Award' at the South Asia Pacific Healthcare Summit & Business Awards, 2019 for his immense contribution to the diagnostic industry.

Our MD, Ms. Ameera Shah won the 'Best Woman Entrepreneur of the Year' in Healthcare Sector award at the ASSOCHAM Women Leadership Awards

Metropolis won the Patient Experience team of the Year Award at PEXA Awards 2019 in Delhi

FINANCIAL HIGHLIGHTS

In INR Crs	Q3FY21	Q3FY20
Revenue from Operations	274.8	222.8
EBIDTA (before CSR & ESOP)	89.7	63.1
EBIDTA (before CSR & ESOP) (%)	32.6%	28.3%
Profit After Tax	58.6	42.0
Profit After Tax (%)	21.3%	18.9%

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Ms. Nadhiya Mali – Corporate Communications

nadhiya.mali@metropolisindia.com

+91-8879009517

www.metropolisindia.com

SGA Strategic Growth Advisors

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah

shogun.jain@sgapl.net / shrenik.shah@sgapl.net

+91-77383 77756 / 96647 64465

www.sgapl.net